Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren

You can read it here...

Media Coverage

July 15, 2020 – European Biotechnology Magazine Summer 2020: Antiviral drug for pandemic preparedness (page 29)
June 5, 2020 – Genetic Engineering & Biotechnology News: Atriva Therapeutics – ATR-002
June 2, 2020 – Pharmazeutische Zeitung: MEK-Inhibitor im Test gegen Covid-19
June 2020 – Nature Biopharma Dealmakers: Atriva Therapeutics: transforming antiviral therapies
May 4, 2020 - Capital: Wirkt das? Biotech gegen Corona
March 24, 2020 – ARD: Kampf um Corona-Medikamente
February 6, 2020 – Handelsblatt: Wie Pharmakonzerne an Mitteln gegen das Coronavirus forschen
January 28, 2020 – SCRIP: Atriva fast tracks antiviral candidate as coronavirus arrives in Germany
January 28, 2020 – Der Tagesspiegel: Therapieansätze gegen das Wuhan-Virus. Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren
July 7, 2019 – LABO: Vier Unternehmen mit "Biomarker Validation Award" ausgezeichnet
March 8, 2019 – Labiotech: Flu resistant to antivirals? This biotech has a drug for that
January 4, 2019 – Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren
2017 – New article published in "Platform Life Sciences" presenting ATRIVA approach
2017 – Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017
2017 – Nature: Host with the most: Targeting host cells instead of pathogens to fight infectious disease

Events & Presentations

Please note that, due to the current coronavirus crisis, many conferences have been canceled or postponed.

September 21-24, 2020 - BioPharm America Digital. Dr. Björn Cochlovius, VP Business Development, will represent the Company and be available for networking and one-on-one meetings.
October 26-29, 2020 - BIO-Europe Digital.

Feel free to contact us any time.

Links

About Us
Contact
Legal Notice
Data Protection

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.

Data Protection Rules I Agree